Observation an Immunogenicity and Safety Study of Modified TRC-ID Regimen With A New Chromatographically Purified Vero Cell Rabies Vaccine (SPEEDA®) With or Without Rabies Immunoglobulin in Children
Sponsor study identifier
observational
45
0 countries
N/A
Study Start
February 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2015
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To determine Immunogenicity and Safety Study of Modified TRC-ID Regimen with A New Chromatographically Purified Vero Cell Rabies Vaccine (SPEEDA®) as post exposure rabies intradermal regimen with or without Rabies Immunoglobulin in Children
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2014
Date type not reportedThis date has not been verified as actual or estimated.
January 7, 2015
Actual (reported)January 16, 2015
Actual (reported)March 2015
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
determine the level of rabies neutralizing antibodies after using SPEEDA® with modified TRC-ID rabies with or without RIG and the safety of using SPEEDA® with modified TRC-ID rabies with or without RIG in children
1 year 6 month
Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times
Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times with ERIG
rabies vaccine 0.1 ml intradermal two site for 4 times
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
recruit the patients from Rabies clinic of Queen Saovabha Memorial Institute, Thammasat Hospital, Charoen Krung Pracha Rak Hospital and HRM Princess Maha Chakri Sirindhorn Medical Center and all had experienced WHO category II or III exposure to suspected rabid animal. In patients with WHO category III have to receive a heterologous biological (ERIG or HRIG)
Rabies Neutralizing antibody
Piyada Angsuwatcharakon, MD
QSMI TRC society
45 participants (actual enrollment reported by the registry).
First Submitted
January 7, 2015
First Posted
January 16, 2015
Study Start
February 2014
Date type not reportedThis date has not been verified as actual or estimated.
Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
Contact the study team to confirm eligibility.
Primary Completion
March 2015
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 16, 2015
Record last verified: 2015-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: